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Abstract 
Since anatomic MRI is presently not able to directly discern neuronal loss in Parkinson’s Disease 
(PD), studying the associated functional connectivity (FC) changes seems a promising approach 
toward developing non-invasive and non-radioactive neuroimaging markers for this disease. While 
several groups have reported such FC changes in PD, there are also significant discrepancies 
between studies. Investigating the reproducibility of PD-related FC changes on independent 
datasets is therefore of crucial importance. 
We acquired resting-state fMRI scans for 43 subjects (27 patients and 16 normal controls, with 2 
replicate scans per subject) and compared the observed FC changes with those obtained in two 
independent datasets, one made available by the PPMI consortium (91 patients, 18 controls) and a 
second one by the group of Tao Wu (20 patients, 20 controls). 
Unfortunately, PD-related functional connectivity changes turned out to be non-reproducible across 
datasets. This could be due to disease heterogeneity, but also to technical differences. To 
distinguish between the two, we devised a method to directly check for disease heterogeneity using 
random splits of a single dataset. Since we still observe non-reproducibility in a large fraction of 
random splits of the same dataset, we conclude that functional heterogeneity may be a dominating 
factor behind the lack of reproducibility of FC alterations in different rs-fMRI studies of PD.  
While global PD-related functional connectivity changes were non-reproducible across datasets, we 
identified a few individual brain region pairs with marginally consistent FC changes across all 
three datasets. However, training classifiers on each one of the three datasets to discriminate PD 
scans from controls produced only low accuracies on the remaining two test datasets. Moreover, 
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classifiers trained and tested on random splits of the same dataset (which are technically 
homogeneous) also had low test accuracies, directly substantiating disease heterogeneity. 
 
Keywords: Reproducibility; Resting state functional connectivity markers; Parkinson's Disease; 
Data sharing 
 
Abbreviations 
PD Parkinson’s Disease 
NC Normal Controls 
rs-fMRI resting state functional Magnetic Resonance Imaging 
FC Functional Connectivity 
ROI Region of Interest 
H&Y Hoehn and Yahr score 
PPMI Parkinson’s Progression Markers Initiative 
SVM Support Vector Machine classifier 
GNB Gaussian Naïve Bayes classifier 
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Introduction 
Although Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s disease, its diagnosis is still difficult, especially in the early premotor stages, as it is 
mainly based on clinical evidence. To date, there is still no unique standard diagnostic test for PD, 
despite the intense research efforts to develop accurate biomarkers based on blood tests or imaging 
scans. The best current objective tests for PD evaluate dopaminergic function in the basal ganglia 
by using various PET or SPECT radiotracers (e.g. DaTSCAN). But these tests make use of 
radioactive substances, are performed only in specialized imaging centers and can also be very 
expensive. Moreover, the loss of dopaminergic nigro-striatal neurons is a delayed pathological 
event in the evolution of the disease, corresponding to Braak stages III-IV. 
On the other hand, conventional (CT or MRI) brain scans of PD patients usually appear normal or 
with minor non-specific changes, so that conventional imaging techniques are only useful for ruling 
out other diseases that can be secondary causes of parkinsonism. 
Therefore, since anatomic MRI is presently not able to directly discern (dopaminergic) neuronal 
loss in PD [Tuite et al., 2013], studying the associated functional connectivity (FC) changes seems 
to be a promising approach toward developing non-invasive and non-radioactive neuroimaging 
markers for this disease. 
While many groups have reported such FC changes in PD (see Supplementary Table 1 for a list of 
such studies), an in-depth analysis of existing literature revealed significant discrepancies between 
studies. Investigating the reproducibility of PD FC changes on independent datasets is therefore of 
crucial importance.  
A comprehensive review and analysis of the literature related to resting-state fMRI studies of 
Parkinson’s disease is out of the scope of the present paper [Gottlich et al., 2013; Long et al., 2012; 
Skidmore et al., 2013; Baudrexel et al., 2011; Wu et al., 2011; Kwak et al., 2010; Kwak et al., 
2012; Helmich et al., 2010; Helmich et al., 2011; Luo et al., 2014; Yu et al., 2013; Hacker et al., 
2012; Kurani et al., 2015; Baggio et al., 2015; Esposito et al., 2013; Szewczyk-Krolikowski et al., 
2014; Tessitore et al., 2012; Sharman et al., 2013; Wu et al., 2012; Liu et al., 2013; Chen et al., 
2015; Wen et al., 2013; Zhang et al., 2015] (Supplementary Table 1; see also the review by 
[Tahmasian  et al., 2015]). We only mention some important inconsistencies of reported functional 
connectivity changes in PD. Due to the crucial importance of the striatum in PD, we first discuss 
some inconsistencies involving striatal seeds [Tahmasian  et al., 2015]: 
 Contrary to [Hacker et al. 2012], [Helmich et al. 2010] observed no significant difference in 
caudate functional connectivity in PD. 
 On the other hand, contrary to the study [Helmich et al., 2010], [Luo, Song, et al. 2014] did not 
observe increased FC of the anterior putamen. 
 In contrast to [Hacker et al., 2012], [Luo, Song, et al. 2014] did not find a FC decrease between 
the striatal seeds and the brainstem. 
There are also inconsistencies involving non-striatal seeds. For example, [Wu et al., 2011] found 
disrupted FC between the pre-SMA and the left putamen, as opposed to [Helmich et al., 2010], who 
did not find a decreased FC between the putamen and pre-SMA in PD.  
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Since the motor symptoms are the most striking clinical manifestations in PD, many rs-fMRI 
studies of PD concentrate on the sensorimotor system, including the basal ganglia, while 
disregarding any other FC changes. On the other hand, other more unbiased studies tried to 
determine a more global picture of the FC changes in PD. Some even tried to develop classifiers for 
the disease based on rs-fMRI data [Long et al., 2012; Skidmore et al., 2013; Szewczyk-
Krolikowski et al., 2014; Chen et al., 2015], but most studies were not validated on independent 
datasets. 
There are also some gross discrepancies involving even the sign of the main FC changes in PD. For 
example, [Luo et al. 2014] found only decreased FC in early stage PD, whereas most studies also 
find FC increases.  
The general picture one gets from the literature is complex and at times somewhat confusing due to 
the numerous inconsistencies. Of course, these inconsistencies could be due to the different disease 
stages analyzed, to the inherent functional heterogeneity of the disease, but also to technical 
differences, or to the differences in the complex data (pre)processing workflows. Therefore, it is 
crucial to use the same data processing workflow to check the reproducibility of PD-related FC 
changes on as many independent datasets as possible.  
In this work, we report a comparison between three different datasets obtained by completely 
independent research groups (see Table 1). More precisely, we acquired resting-state scans for 43 
Romanian subjects (27 patients and 16 normal controls, with 2 replicate scans per subject) and 
compared the observed functional connectivity changes with those obtained in two independent 
datasets, one made available by the PPMI consortium in the US (91 patients, 18 controls) and a 
second one by the group of Tao Wu in China (20 patients and 20 normal controls). 
 
Table 1. The 3 PD datasets compared in the present study (PD=Parkinson’s Disease, 
NC=normal controls). 
Dataset 
PD 
subjects 
NC 
subjects 
PD 
scans 
NC 
scans 
age PD 
mean(SD) 
age (NC) 
mean (SD) 
p 
(age 
NC-
PD) 
Hoehn & 
Yahr 
mean(SD) 
disease 
duration 
mean(SD) 
NEUROCON 27 (16 M) 16 (5 M) 54 31 68.7 (10.6) 67.6 (11.9) 0.76 1.92 (0.33) 4.6 (6.5) 
Tao Wu 20 (11 M) 20 (12 M) 20 20 65.2 (4.4) 64.8 (5.6) 0.78 1.88 (0.63) 5.4 (3.9) 
PPMI 91 (63 M) 18 (14 M) 134 19 61.3 (10.2) 64.7 (9.7) 0.17 1.72 (0.48) 1.9 (1.0) 
 
We briefly describe our approach in Fig 1A to better guide the reader through the remainder of the 
paper. We started by comparing the PD-related global functional connectivity changes in the 3 
datasets and found them to be non-reproducible. Of course, this could be due to disease 
heterogeneity, but also to technical differences. To better distinguish between these two 
possibilities, we devised a method to directly check for disease heterogeneity using random splits 
of a single dataset. On the other hand, we searched for individual brain region pairs with consistent 
connectivity changes across all three datasets. Finally, to more directly discriminate PD scans from 
controls, we trained multivariate machine learning classifiers on one dataset and tested them on the 
remaining two. Additionally, we trained and tested classifiers on technically homogeneous random 
splits of the same dataset, to more directly check for disease heterogeneity. 
 
 5 
 
Fig 1. Overview. (A) Main steps of the analysis. (B) Using random splits of a dataset with replicate 
scans to check for disease (group) heterogeneity: (a, right) by placing different subjects (with all 
their replicate scans) in the two splits (“split subjects”) and respectively (b, left) by splitting the 
replicates of the same subjects in the two splits (“split replicates”). The “split replicates” datasets 
must show reproducible changes anyway, while non-reproducible changes across the “split 
subjects” datasets are an indication of disease heterogeneity. (a,b,c,... correspond to subjects, while, 
for instance, a’ and a” are replicate scans for subject a.) 
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This is the first study investigating the reproducibility of functional connectivity changes in 
Parkinson’s disease on more than 2 datasets. Given the paucity of publicly available rs-fMRI PD 
datasets, we advocate the critical importance of data sharing for enabling the discovery of 
reproducible rs-fMRI biomarkers of PD.  
 
Materials and Methods 
Datasets 
Three resting-state fMRI datasets of Parkinson’s disease were compared in this study (see also 
Table 1 for the main patient characteristics and the numbers of scans in each study): 
- the NEUROCON rs-fMRI study of 27 PD patients and 16 normal controls of the Neurology 
Department of the University Emergency Hospital Bucharest (Romania), 
- a dataset of 20 PD patients and 20 normal controls provided by the group of Tao Wu (China), 
- a publicly available dataset of 91 PD patients and 18 controls of the Parkinson’s Progression 
Markers Initiative (PPMI) study in the US. 
The datasets are somewhat similar, except for PPMI, which involved patients with a diagnosis of 
PD for two years or less and who are not taking PD medications, while most patients from the other 
two studies have been under treatment (most under levodopa). Also, PPMI patients were scanned in 
the ‘eyes open’ condition. Still, we argue that our findings were not affected by these differences. 
Since the datasets were compared in a pairwise manner, any putative discrepancies due to the 
shorter disease durations in the PPMI dataset would only show up in the NEUROCON-PPMI and 
Tao Wu-PPMI comparisons, but not in the NEUROCON-Tao Wu comparison. This was not 
observed in reality. 
NEUROCON 
The NEUROCON study enrolled 27 patients with Parkinson’s disease (mean age±SD 68.7±10.6 
years) and 16 age-matched normal controls (67.6±11.9 years) with no history of neurological or 
psychiatric disease. The patients were clinically assessed at the Neurology Department of the 
University Emergency Hospital Bucharest (Romania) to be in the early or moderate stage of the 
disease according to the Queen Square Brain Bank (QSBB) clinical criteria and met the 
EFNS/MDS-ES (European Federation of Neurological Societies/Movement Disorder Society–
European Section) recommendations for diagnosis of Parkinson’s disease. The mean disease 
duration was 4.6 (±6.5) years for the entire patient cohort and respectively 2.75 (±2.15) years after 
excluding three patients with particularly long disease durations (over 10 years: 11, 16 and 32 years, 
respectively). Despite the longer disease durations, the above-mentioned 3 patients met the criteria 
for moderately advanced disease (H&Y stage 2) and thus were included in the study. The mean 
Hoehn and Yahr (H&Y) score [Hoehn and Yahr, 2001] was 1.93 (±0.33) and respectively 1.92 
(±0.35) after excluding the 3 patients with long disease durations. All patients were in an early to 
moderate stage of disease (stages 1 to 2.5). The mean score on the motor subset of the Unified 
Parkinson’s Disease Rating Scale (UPDRS) [Fahn, 1986] in the off medication condition was 28.3 
(±9.3) for the entire patient cohort and 26.9 (±8.8) after excluding the 3 patients with long disease 
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durations. The study has been approved by the University Emergency Hospital Bucharest ethics 
committee in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later 
amendments. All patients gave their written informed consent to participate in the study. 
Scanning. All subjects underwent two consecutive 8 min fMRI scans in a 1.5-Tesla Siemens 
Avanto MRI scanner, in an awake resting state with their eyes closed. Two consecutive replicate 
scans were acquired for each subject to enable the study of the reproducibility and respectively 
homogeneity of FC changes in PD. (A single (control) subject could only be scanned once.) The 
patients were scanned in the “off medication” state, at least 10 hours after the last intake of their 
medication. The scanning protocol involved an Echo Planar sequence with repetition time (TR) 
3480 ms, echo time (TE) 50 ms, axial orientation, voxel size 3.8×3.8×5 mm (without slice gaps), 
flip angle 90 and number of averages=1. Each resting state session lasted 8.05 min, comprising 
137 volumes. To enable better co-registration to the standard MNI template, high-resolution T1-
weighted images were also obtained for all subjects using an MPRAGE sequence (IR method, 
TR=1940ms, TE=3.08ms, inversion time (IT)=1100ms, voxel size 0.97×0.97×1 mm, number of 
averages=1).  
Tao Wu 
The dataset comprised 20 PD patients (11 males, mean age±SD 65.2±4.4 years) and 20 age-
matched normal controls (12 males, 64.8±5.6 years). All patients were in the early to moderate 
stage of the disease (Hoehn and Yahr stages 1 to 2.5, except for a single patient with H&Y stage 3) 
and had normal Mini-Mental State Examination (MMSE) scores. Moreover, there was no 
statistically significant MMSE difference (p=0.43) between PD patients (28.8±1.1) and normal 
controls (29.1±1.3). 
Scanning. Both resting state fMRI and anatomic T1 scans were acquired for the 40 subjects in a 
Siemens Magnetom Trio 3T equipment, in an awake resting state with their eyes closed. Each 
resting state session lasted about 8 min (239 volumes, TR=2s,  TE=40 ms, flip angle=90) with a 
voxel size of 4×4×5 mm (6464 matrix, 28 slices, field of view=256mm×256mm). MPRAGE 
scans were also obtained (voxel size 1×1×1 mm) for registration to the MNI template. 
PPMI 
Imaging data for 91 PD patients (63 males) and 18 normal controls (14 males) were downloaded 
from the Parkinson’s Progression Markers Initiative (PPMI) study data portal (http://www.ppmi-
info.org/access-data-specimens/download-data/, 
https://ida.loni.usc.edu/home/projectPage.jsp?project=PPMI) with the kind permission of the PPMI 
consortium. The study includes patients with a diagnosis of PD for two years or less and who are 
not taking PD medications. The patients and controls are age-matched (p=0.17, mean age±SD 
61.3±10.2 years for the PD patients and respectively 64.7±9.7 years for the normal controls). The 
patients had a mean Hoehn & Yahr score of 1.72 (SD 0.48), with a mean disease duration (at the 
time of the scan) of 1.9 years (SD 1.0). All patients had H&Y scores 1 to 2, except for only two, 
who were classified as H&Y stage 3. 
Scanning. The subjects were scanned in 8 different centers, but with a similar protocol on Siemens 
Tim Trio 3Tesla scanners. Each resting state session lasted about 8.4 min (210 volumes, TR=2.4s, 
TE=25ms, flip angle 80) with a voxel size of 3.3×3.3×3.3 mm (6866 matrix, 40 slices). Subjects 
were instructed to rest quietly, keeping their eyes open and not to fall asleep. MPRAGE scans were 
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also obtained (voxel size 1×1×1 mm, TR=2.3s, TE=2.98ms, flip angle=9) for registration to the 
MNI template. 
Although our functional connectivity computations did not require any particular type of data 
normalization (as only inter-region correlations are computed, rather than amplitudes), we also 
considered a subset of scans acquired in a single center (center number 32, with the largest number 
of PD patient and normal control scans), referred to in the following by the suffix ‘center32’. 
Preprocessing 
All datasets were preprocessed in a uniform manner. The raw scanner data in DICOM format was 
converted to NIfTI using dcm2nii (https://www.nitrc.org/projects/dcm2nii/) and further 
preprocessed using FSL (FMRIB Software Library v5 http://fsl.fmrib.ox.ac.uk/fsl/) as follows: 
motion correction using MCFLIRT, brain extraction with BET, spatial smoothing (Gaussian kernel 
FWHM 5mm) and denoising using nonlinear filtering (SUSAN), temporal high-pass filtering (with 
a cutoff frequency of 0.01 Hz), registration to the standard Montreal Neurological Institute 
MNI152 template via the anatomical T1 image (more precisely, BBR registration of the BOLD 
image to the T1 image, followed by 12 DOF linear+nonlinear registration of the latter to the 2mm 
MNI template). Nonlinear registration was performed at a resampling resolution of 4mm. 
Besides the above ‘standard’ preprocessing workflow, we also considered alternative workflows 
involving global signal regression (GS) and respectively a temporal bandpass filter (0.01-0.1Hz – 
an ideal low-pass 0.1Hz filter was used in addition to the default FSL 0.01Hz highpass filter). 
Since subject motion in the scanner has been observed to have significant influence on the 
functional connectivities computed from rs-fMRI data, despite motion correction (e.g. [Power et al., 
2015]), we also considered subsets of scans with low in-scanner motion (marked by the suffix ‘0’, 
e.g. ‘NC0’ and ‘PD0’ – see also Supplementary Table 2). 
PD-related functional connectivity changes 
Functional connectivity [Friston and Buchel, 2003] is a rather loosely defined term, which 
encompasses many different methods used to reveal temporal correlations of BOLD activity across 
the brain. The simplest method consists in computing the correlations between all pairs of regions 
of a given brain parcellation, but more sophisticated data decomposition methods, such as 
Independent Component Analysis (ICA) are also widely used. Such data decomposition methods 
do not assume a given brain parcellation, but instead construct spatial maps grouping voxels with 
highly correlated timecourses. (Still, instead of being given a parcellation, such methods need to be 
provided with a target number of components.) 
In our study of the reproducibility of functional connectivity changes in PD, we used brain 
parcellations constructed independently of the datasets under comparison, rather than applying 
data decomposition methods, such as group-ICA, since the latter would be inherently biased 
towards the “training dataset”. Group-ICA may obtain a better functional parcellation for the 
training dataset, but that parcellation would be less appropriate for any other independent dataset 
(“overfitting”), thereby introducing a bias in the analysis. To avoid these problems, we have chosen 
to use brain parcellations constructed independently of the datasets under comparison, including 
functional brain parcellations obtained by group-ICA on  completely independent sets of subjects 
(such as the ‘Stanford’ functional parcellation [Shirer et al., 2011]). 
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Moreover, to compensate for potential biases of any specific parcellation, we extended our analyses 
to a number of 13 different parcellations employed in other rs-fMRI studies, two anatomical (AAL, 
Talairach) and 11 functional (see Table 2 for more details).  
Table 2. The brain parcellations used in the functional connectivity comparisons. 
Parcellation Reference 
Number of 
regions 
Comments 
AAL 
[Tzourio-Mazoyer et 
al., 2002] 
116 anatomic atlas 
Craddock 130 
[Craddock et al., 2012] 
130  
Craddock 260 260  
Craddock 500 500  
Craddock 950 950  
Shen 100 
[Shen et al., 2013] 
93  
Shen 200 183  
Shen 300 278  
OASIS [Marcus et al., 2007] 97  
Power [Power et al., 2011] 264 spherical regions with a 10mm radius  
Gordon_surface [Gordon et al., 2014] 333  
Talairach 
[Talairach and 
Tournoux, 1988] 
695 anatomic atlas 
Stanford [Shirer et al., 2011] 90  
functional parcellation obtained by 
group-ICA 
 
For each parcellation, we computed average timecourses for each region of interest (ROI) and the 
resting state functional connectivity between each pair of ROIs (ROI1,ROI2) as the Fisher z-
transform of the temporal correlation between the corresponding ROI timecourses: 
FC(ROI1,ROI2) = z(corr(ROI1,ROI2)). 
For each dataset, we determined significant PD-related FC changes by applying two-sample t-tests 
(with unequal sample sizes and unequal variances) to the functional connectivities of all ROI pairs. 
ROI-pairs with significant group differences (NC versus PD) represent regions whose functional 
connectivity was found to be significantly different in PD patients in that particular dataset. The 
main aim of this study is to determine whether these changes are reproducible across datasets, to 
enable the development of functional imaging biomarkers for PD. 
Reproducibility of global functional connectivity changes in PD 
Comparison of 3 different PD datasets 
We first compared the global PD-related functional connectivity changes across the three 
independent datasets NEUROCON, Tao Wu and PPMI to check to what extent these changes are 
reproducible. More precisely, we performed pairwise comparisons for all dataset pairs as follows.  
For each pair of datasets (i,j) and a fixed parcellation, we checked the extent to which the PD-
related FC changes in one dataset are correlated to the changes in the second dataset.  
 10 
PD-related FC changes were quantified using t-values t(ROIk,ROIl) from group comparisons 
(unpaired two-sample t-tests between NC and PD) of the functional connectivities between pairs of 
regions of interest FC(ROIk,ROIl). 
Then the reproducibility Rij across the two datasets i and j was determined as the correlation 
between the corresponding t-values (viewed as a vector over all ROI pairs) for the two datasets: 
 Rij = corr(Ti,Tj), (1) 
where  
Ti=(ti(ROI1,ROI2), ti(ROI1,ROI3), ti(ROI1,ROI4), ) 
with ti(ROIk,ROIl) the t-value corresponding to PD-related FC changes between ROIk and ROIl 
with respect to dataset i (and similarly Tj for dataset j). 
For a more intuitive graphical depiction of reproducibility across two datasets, we also constructed 
the scatter-plot of ROI-pair t-values corresponding to group comparisons in the two datasets (see 
Fig 2 for an example of such a scatter-plot).  
Comparing PD-related FC changes (t-values) in the two datasets amounts to plotting for each ROI-
pair the t-value in dataset 1 against the t-value in dataset 2. We thereby obtain a scatter-plot with a 
point for each ROI pair. The comparison of the FC changes in the two datasets thus involves 
analyzing the distribution of points in the scatter-plot: ideally, perfect reproducibility would entail a 
diagonal distribution of points in the scatter-plot, corresponding to perfectly correlated t-values in 
the two datasets. Fig 4 depicts examples of good reproducibility, while Fig 2 shows cases of non-
reproducibility across datasets.  
The correlation of t-values for the two datasets Rij = corr(Ti,Tj), as introduced above in (1), can be 
viewed as an aggregate measure of the reproducibility across the two datasets i and j.  
To obtain a more quantitative measure of the statistical significance of such a correlation Rij 
between datasets, we performed permutations of the group labels (NC and PD) independently for 
the two datasets and computed the p-value of the Rij value as the fraction of permutations  for 
which the dataset correlation w.r.t. the permuted data Rij
()
 exceeds the real one (Rij): 
 pij = |{ permutation  | Rij
()
  Rij }| / N, (2) 
where N is the total number of permutations. All our permutation tests involved N=1000 
permutations. 
Various factors have been mentioned in the literature to affect functional connectivity measures: 
- subject motion in the scanner [Power et al., 2015], 
- global signal regression (with or without) [Murphy et al., 2009; Hayasaka 2013], 
- the choice of the parcellation. 
To study the influence of these factors on our reproducibility results, we also considered subsets of 
scans with low in-scanner motion (marked by the suffix ‘0’, e.g. ‘NC0’ and ‘PD0’), repeated our 
analyses with global signal regression, bandpass filtering and performed the comparisons using all 
13 brain parcellations previously mentioned. Since the PPMI data has been acquired in several 
different imaging centers, we also considered a potentially more homogeneous subset of scans 
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acquired in a single center (center number 32, with the largest number of PD patient and normal 
control scans), referred in the following by the suffix ‘center32’. 
Comparison of random splits of the same PD dataset 
As already mentioned in the Introduction, the observed lack of reproducibility of global FC 
changes across datasets could be due to disease heterogeneity, but also to technical differences. To 
distinguish between these two possibilities, we devised a method to directly check for disease 
heterogeneity using random splits of a single dataset with replicate scans. Technical differences can 
then be excluded since all the scans have been acquired under identical technical conditions. More 
precisely, since in the NEUROCON study we acquired two replicate scans for each subject, we 
constructed two homogeneous dataset splits simply by using (different) scans of the same subjects. 
Additionally, two heterogeneous dataset splits can be obtained by placing different subjects (with 
all their scans) in each split. In other words, instead of comparing two distinct datasets, we 
compared two random splits of the same dataset, either: 
(a)  by placing different subjects in the two splits, with all the replicate scans of a subject in the 
same split (“split subjects”, heterogeneous split), or  
(b)  by placing each replicate scan of the same subject in a different split, so that the two splits 
contain (different) scans of the same subjects (“split replicates”, homogeneous split). 
Dataset splits (b) are homogeneous since they contain scans of the same subjects, while splits (a) 
are heterogeneous since they contain scans of different subjects. Therefore, consistent 
reproducibility across all random heterogeneous splits would indicate disease homogeneity, while 
non-reproducibility in a large fraction of random heterogeneous splits would imply disease 
heterogeneity. (In both cases, we expect to observe consistent reproducibility across the 
homogeneous splits, at least as long as the technical noise is not dominating the biological signal.) 
A diagram of our method is shown in Fig 1B. 
As in the pairwise comparisons between different datasets, we used permutation tests and formula 
(2) to compute p-values of the reproducibility across split datasets, for both the heterogeneous 
(“split subjects”) and the homogeneous (“split replicates”) datasets. Due to the random nature of 
the splits, we repeated the analysis for Ns > 1000 different random splits of the original data. To 
assess the fraction of (non-)reproducible splits, we determined the empirical cumulative 
distribution function (CDF) of the reproducibility p-values for the Ns random splits. 
The analysis was also repeated for the data with global signal regression. 
Influence of technical factors, preprocessing and parcellation 
We also studied the influence on reproducibility of certain key technical factors and preprocessing 
steps, such as: 
- the repetition time (TR), 
- linear vs. nonlinear registration, 
- global signal regression, 
- the specific brain parcellation used for evaluating functional connectivity. 
The AAL parcellation (which is typical) was used whenever not specified otherwise. 
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Doubling the TR 
The repetition time might, in principle, influence the measured low-frequency rs-fMRI fluctuations 
and indirectly the functional connectivities (which are temporal correlations). To study the 
influence of the repetition time on reproducibility, we constructed a synthetic dataset with a double 
TR by leaving out every second time-point from the NEUROCON timeseries data (for each scan 
and each voxel). We then analyzed with our method the reproducibility of group changes in 
functional connectivity between the original NEUROCON dataset and the synthetic one with a 
double TR. 
Linear vs. nonlinear registration 
To study the impact of registration on reproducibility, we preprocessed the NEUROCON data both 
with linear and nonlinear registration to the MNI 152 template and determined the reproducibility 
of group changes in functional connectivity between the two resulting datasets. 
Global signal regression 
Since global signal regression (GSR) has been observed to be very effective at removing scanning 
artifacts [Hayasaka, 2013], including motion artifacts, we also studied the reproducibility of FC 
changes between the NEUROCON dataset processed with GSR and the same dataset processed 
without GSR. 
Influence of parcellation 
To avoid potential biases of any specific parcellation, we repeated our pairwise comparisons 
between the 3 PD datasets using all 13 different parcellations mentioned above, including 
functional and anatomic parcellations, with a wide range of numbers of regions of interest (90 to 
950). 
Reproducibility of the individual differentiating FC changes 
The reproducibility analysis performed above involves global functional connectivity changes, i.e 
changes in the FC of all ROI pairs, not just the ones that differentiate PD from normal controls. 
Even with non-reproducible global FC changes, it might be in principle possible that only a very 
few brain region pairs might still reproducibly differentiate PD patients from controls. To this end, 
we also studied individual brain region pairs with FC changes that are significant w.r.t. all datasets.  
More precisely, for each ROI-pair, we compute max(p), the largest (least significant) of the three p-
values obtained in the three datasets (separately for the FC increases and respectively decreases) 
and sort the ROI-pairs in increasing order of this max(p). The most significant min(max(p)) of these 
max(p) corresponds to the ROI-pair with the best overall significance with respect to the 3 datasets, 
as all other ROI-pairs have larger (less significant) p-values with respect to at least one dataset. 
Finally, to assess the statistical significance of such a best ROI-pair, we use a permutation test (of 
the disease labels in each dataset) to check the fraction of random permutations with a more 
significant (smaller) min(max(p)) than the real data (we performed N=1000 random permutations). 
p(min(max(p+))) = |{ permutation  | min(max(p+))
()
  min(max(p+)) }| / N, 
where min(max(p+)) corresponds to FC increases in NC versus PD. A similar relation holds for the 
FC decreases min(max(p)). 
The analysis was repeated for all 13 parcellations considered in this study (Table 2). 
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Learning classifiers for discriminating PD-related FC changes 
We used machine learning techniques to learn classifiers that discriminate PD from controls using 
functional connectivities between ROI pairs as features.  
First, we trained classifiers on each one of the 3 datasets (NEUROCON, Tao Wu, PPMI) and tested 
them on the other two datasets. Both Linear Support Vector Machines (SVM) and Gaussian Naïve 
Bayes (GNB) classifiers were tested, with progressively increasing numbers of features: 
N=10,50,100,500,5000 (functional connectivities between ROI pairs). The N features selected were 
the best discriminating ROI pair functional connectivities, based on unpaired t-tests between 
normal and PD scans. As the two classes (NC-Normal Controls and PD-Parkinson’s Disease) are 
not balanced in all 3 datasets, we employ the average accuracy Aacc = (acc(NC)+acc(PD))/2 for 
assessing the performance of the classifiers (a random classifier is expected to have an average 
accuracy of 0.5). 
Since the different datasets are not technically homogeneous, we also trained and tested classifiers 
on random splits of the same dataset, to check to what extent the low accuracies are due to 
technical differences, or to disease heterogeneity. More precisely, we performed 10,000 random 
splits in half of each dataset, trained a classifier on one half and tested it on the other. 
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Results 
ROI-pairs with significant group differences (NC versus PD) in functional connectivity were found 
in all three PD datasets: NEUROCON, Tao Wu and PPMI (Supplementary Tables 3 and 4). 
However, these changes seemed at first sight to be distinct in each dataset. Our main aim in this 
paper has been to systematically investigate the reproducibility of the PD-related FC changes 
across independent validation datasets. 
PD-related FC changes are non-reproducible across 3 datasets 
The reproducibility of global PD-related functional connectivity changes was determined by 
pairwise comparisons between three independent datasets: NEUROCON, Tao Wu and respectively 
PPMI. Fig 2 shows the scatter-plots of ROI-pair t-values (corresponding to the group comparison 
NC-PD) for the three dataset pairs, indicating a lack of reproducibility of global FC changes in PD. 
(Perfect reproducibility would correspond to a diagonal distribution of points corresponding to ROI 
pairs with perfectly correlated t-values with respect to both datasets.) Moreover, discriminating 
ROI-pairs situated in the upper right and respectively lower left corners of one plot are not 
discriminating in the other plots. 
 
 
Fig 2. Scatter-plots of ROI-pair t-values for the three dataset pairs indicate non-
reproducibility of global PD-related FC changes.  
 
For a more quantitative measure of the reproducibility of FC changes between two datasets, we 
computed the Pearson correlation between t-values (viewed as vectors of over all ROI pairs) with 
respect to each dataset (R values shown in Fig 2.) We also estimated the statistical significance (p-
values) of these reproducibility measures by permutation tests of the group labels independently for 
the two datasets – Table 3 shows the reproducibility measure and associated p-value for various 
pairwise comparisons between the three datasets, with standard highpass preprocessing (>0.01Hz), 
global signal regression (GS) and respectively bandpass filter (0.01-0.1Hz). Since in-scanner 
motion may influence FC measures, we present not only a comparison between the full patient and 
normal control cohort, but also that corresponding to a subset of scans with low in-scanner motion 
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(denoted by the suffix ‘0’). Moreover, since PPMI data were acquired at many different centers, we 
also considered the restriction of the PPMI data to the scans from a single center (suffix ‘center32’). 
The AAL parcellation was used in this case, but we also study the influence of the parcellation later 
on. 
Table 3. Reproducibility measure R and associated p-value p for various pairwise 
comparisons between datasets with standard highpass preprocessing (‘standard’), global signal 
regression (GS) and respectively bandpass filter (BP) (‘0’ indicates ‘low in scanner motion’, 
‘center32’ – scans performed at a single PPMI center). 
Dataset 1 
Group 
contrast 1 
Dataset 
2 
Group contrast 
2 
standard GS BP 
R p R p R p 
NEUROCON 
NC-PD 
Tao Wu 
NC-PD -0.145955 0.949 -0.0679698 0.804 0.000845579 0.476 
NC0-PD0 NC0-PD0 -0.0832455 0.847 0.035725 0.300 0.0132475 0.437 
NEUROCON 
NC-PD 
PPMI 
NC-PD 0.0692377 0.257 0.10039 0.138 -0.163251 0.937 
NC0-PD0 NC0-PD0 0.0401831 0.352 0.0308243 0.373 -0.0824776 0.800 
NC-PD 
NC_center32-
PD_center32 
-0.0122797 0.526 0.0188561 0.430 -0.142598 0.914 
NC0-PD0 
NC0_center32-
PD0_center32 
-0.0873994 0.813 -0.0894912 0.832 -0.152545 0.945 
Tao Wu 
NC-PD 
PPMI 
NC-PD 0.00673472 0.466 0.0228885 0.403 0.0948706 0.153 
NC0-PD0 NC0-PD0 -0.0182896 0.560 0.044843 0.298 0.0545817 0.293 
NC-PD 
NC_center32-
PD_center32 
-0.0446155 0.687 -0.032841 0.666 0.0243423 0.400 
NC0-PD0 
NC0_center32-
PD0_center32 
-0.0712155 0.812 -0.0176842 0.597 -0.0436096 0.681 
 
A clear lack of reproducibility of global PD-related FC changes is observed in all the three dataset 
pairs. This is the first study comparing three independent rs-fMRI datasets of PD. The fact that we 
compare 3 datasets is very important, as it lowers the probability that the lack of reproducibility is 
due to a dataset that may be “faulty” in some sense – in that case, with 3 datasets we might still 
observe reproducibility with respect to the remaining dataset pair (which we do not see in reality). 
Inconsistent reproducibility of FC changes in heterogeneous 
dataset splits indicate disease heterogeneity 
The non-reproducibility across 3 datasets mentioned above seems to be due to disease 
heterogeneity, but it could also be due to technical differences. To exclude the latter possibility, we 
checked for disease heterogeneity using random splits of a single dataset with replicate scans 
(NEUROCON), all of which have been acquired under identical technical conditions. 
(a) We first constructed random splits by placing different subjects in the two splits, with all the 
replicate scans of a subject in the same split (“split subjects”, heterogeneous splits). As can be seen 
in Fig 3A (blue curve), a large fraction of these random splits display non-reproducible functional 
connectivity changes. More precisely, 88% of the random heterogeneous splits show non-
reproducibility at the p>0.01 level and 42% at the p>0.05 level. Fig 3B shows the complementary 
cumulative distribution function (1-CDF) for the corresponding reproducibility measure R (blue 
curve), while Fig 3C presents a typical scatter-plot of ROI-pair t-values for a random 
heterogeneous split (one with R equal to the median). 
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Fig 3. Inconsistent reproducibility of PD-related FC changes in random heterogeneous dataset 
splits and consistent reproducibility in random homogeneous dataset splits. (A) 
Complementary cumulative distribution function (CCDF=1-CDF) of the reproducibility p-values 
for Ns=2510 random heterogeneous splits and Ns=325 random homogeneous splits. (B) CCDF of 
the reproducibility measure R. (C) A scatter-plot of ROI-pair t-values for a random heterogeneous 
split. (D) A scatter-plot of ROI-pair t-values for a random homogeneous split.   
 
(b) Next, we constructed random splits by placing each replicate scan of the same subject in a 
different split, so that the two splits contain (different) scans of the same subjects (“split replicates”, 
homogeneous splits). In contrast to (a), all homogeneous splits showed reproducibility at the p<10
-3
 
level (Fig 3A, red curve). Fig 3B shows the complementary CDF for the reproducibility measure 
(red curve) – note the significantly higher reproducibility (R) values for the homogeneous splits 
(red curve, median R=0.71) as compared to the heterogeneous splits (blue curve, median R=0.21). 
Fig 3D displays a typical scatter-plot of ROI-pair t-values for a random homogeneous split. 
The observed non-reproducibility in a large fraction of heterogeneous dataset splits indicates 
disease heterogeneity, in line with the comparison between the 3 independent PD datasets. As a 
control, we did indeed observe consistent reproducibility with respect to all homogeneous dataset 
splits, demonstrating that the technical noise could not have been the dominating factor behind the 
erratic non-reproducibility in heterogeneous splits. 
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The fact that the well-known clinical heterogeneity of Parkinson’s disease is also accompanied by 
heterogeneity in resting state functional connectivity may not retrospectively be a big surprise to an 
experienced neurologist, although its exact extent could not have been estimated a priori, before 
analyzing the data. However, does this FC heterogeneity in PD also imply the lack of practical 
usefulness of rs-fMRI functional connectivity? Are there any other conditions that can be reliably 
differentiated using resting state functional connectivity? To answer these questions, we applied 
our approach to a different, potentially more homogeneous contrast, namely that between eyes 
open and eyes closed resting state conditions in healthy volunteers. Repeating our analysis of 
reproducibility of FC group changes on random splits of the Beijing eyes open-eyes closed dataset 
[Liu et al., 2013] (see Supporting Information) revealed reproducibility (p<0.05) not just in the 
homogeneous dataset splits, but also in the heterogeneous ones (Supplementary Fig 1 – only 6% of 
the heterogeneous and just 0.8% of the homogeneous random splits were non-reproducible at the 
p>0.05 level).  
Summing up our findings, from the point of view of global FC changes, Parkinson’s disease is 
heterogeneous, as opposed to the eyes open-eyes closed contrast, which is much more 
homogeneous (Table 4). 
 
Table 4. Summary of reproducibility of global functional connectivity changes in Parkinson’s 
Disease and respectively the Eyes Open-Eyes Closed contrast. 
Reproducibility of 
global FC changes 
PD EO-EC 
different datasets no  
split subjects  
(heterogeneous splits)   
inconsistent  
(no in a large 
fraction of splits) 
yes 
split replicates 
(homogeneous splits) 
yes yes 
 
Influence of technical factors and preprocessing on reproducibility 
We found good reproducibility when changing various technical factors or processing options of 
the NEUROCON data, such as (see Fig 4): 
- doubling the repetition time (TR), 
- registration (linear versus nonlinear), 
- global signal regression (with versus without). 
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Fig 4. Reproducibility when changing various technical factors or preprocessing options. 
 
This is in line with our conclusion that functional heterogeneity, rather than these technical factors, 
is the dominating factor behind the lack of reproducibility of FC changes in different rs-fMRI 
studies of Parkinson’s disease. 
We also tested the influence of various rs-fMRI denoising methods on the reproducibility of PD-
related FC changes, such as ICA-FIX [Griffanti et al., 2014; Salimi-Khorshidi et al., 2014], or 
regression of the mean white matter and/or cerebrospinal fluid signal – none of these denoising 
methods changed the observed non-reproducibility (data not shown).  
We also observed no improvement in reproducibility across random splits of the NEUROCON 
dataset after regressing out potential confounders, such as age, gender, or disease duration (data not 
shown). 
Influence of parcellation on reproducibility 
We have argued that functional connectivity must be computed with respect to an unbiased 
parcellation (i.e. one that hasn’t been constructed from any of the analyzed datasets). However, any 
given parcellation has also specific biases that may in principle affect the capacity to discriminate 
between PD and normal controls – an especially relevant factor is the average size and number of 
the ROIs. Testing the reproducibility of the PD-related global FC changes using 13 different 
parcellations, with varying numbers of ROIs (between 90 and 950, see Table 2), revealed a lack of 
reproducibility regardless of parcellation, or dataset pair (Table 5). (The NEUROCON-PPMI 
comparison was marginally significant (p=0.05) for the NC-PD contrast, but this significance 
didn’t survive perturbations such as selecting just the ‘center32’ scans from PPMI (p=0.259), or 
restriction to the low motion scans NC0-PD0 (p=0.26),  or NC0-PD0_center32 (p=0.555).) 
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Table 5. Reproducibility measure and associated p-value for 13 parcellations and all three 
dataset pairs (NC-PD contrast). 
Parcellation 
NEUROCON-TaoWu NEUROCON-PPMI TaoWu-PPMI 
R p R p R p 
Craddock130 -0.011116 0.554 0.0927652 0.191 -0.0613781 0.747 
Craddock260 -0.00871389 0.560 0.0775174 0.205 -0.0770479 0.864 
Craddock500 0.00488102 0.469 0.079955 0.172 -0.0546894 0.839 
Craddock950 0.00952484 0.409 0.0694818 0.174 -0.0347004 0.748 
Shen100 -0.0490741 0.708 0.0958863 0.187 -0.0567748 0.734 
Shen200 -0.032232 0.641 0.0936098 0.172 -0.0618746 0.799 
Shen300 -0.0247647 0.632 0.0829943 0.159 -0.0729234 0.871 
OASIS 0.00698018 0.482 0.0205063 0.411 -0.0155159 0.598 
Power264 0.0533032 0.166 0.0812484 0.141 -0.0153593 0.600 
Gordon_surface 0.0381087 0.262 0.025185 0.391 -0.0435482 0.748 
Talairach -0.0273596 0.686 0.0263891 0.357 0.0598013 0.129 
Stanford -0.0600487 0.730 0.185859 0.050 -0.081526 0.819 
AAL -0.145955 0.949 0.0692377 0.257 0.00673472 0.466 
 
Marginally significant individual differentiating FC changes in PD 
Despite non-reproducibility of PD-related global FC changes across different datasets, a small 
number of ROI-pairs that distinguish PD from controls may nevertheless, in principle, show 
reproducible changes across datasets. To check for this possibility, we concentrated on individual 
brain region pairs with FC changes that are significant w.r.t. all datasets, by sorting the ROI-pairs 
according to their least significance max(p) with respect to all datasets.  
For example, Table 6 shows the ROI-pairs with FC decreases in PD (i.e. positive t-values, 
corresponding to NC>PD) and max(p) < 0.05 for the Power264 parcellation, without global signal 
regression. The best ROI-pair has max(p+)=0.0125, so min(max(p+))=0.0125. 
To check whether this min(max(p+)) is statistically significant, we performed permutation tests as 
described. Table 7 lists these min(max(p)) values as well as their associated significance 
p(min(max(p))) for all 13 parcellations. Only two out of the 13 parcellations yielded significant 
ROI-pairs at the p<0.05 significance level (‘Power264’ and ‘Talairach’), while a third parcellation 
produced only marginally significant ROI-pairs (‘Shen100’, p=0.055) - see Table 8 and Fig 5. 
These (marginally) significant ROI-pairs involve visual-sensorimotor, respectively visual-parietal 
association areas. Whether these ROI-pair changes are more widely reproducible or not will have to 
await the release of more publicly-available PD rs-fMRI datasets. 
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Table 6. Best ROI-pairs with FC decreases in PD (t>0, corresponding to NC>PD) and max(p) 
< 0.05 (for the Power264 parcellation, without global signal regression). 
max(p) ROI1-ROI2 
p 
NEUROCON 
(NC-PD) 
p TaoWu (NC-
PD) 
p PPMI (NC-
PD) 
t 
NEUROCON 
(NC-PD) 
t TaoWu 
(NC-PD) 
t PPMI (NC-
PD) 
0.012526 
sphere5(-21,-31,61)-
sphere5(15,-77,31) 
0.012526 0.0018915 0.011638 2.5541 3.3398 2.7402 
0.016354 
sphere5(-42,45,-2)-
sphere5(43,-78,-12) 
0.0026347 0.016354 0.0079673 3.1172 2.5153 2.905 
0.025311 
sphere5(-21,-31,61)-
sphere5(-24,-91,19) 
0.0019939 0.025311 0.025232 3.2025 2.3298 2.3949 
0.038357 
sphere5(-38,-33,17)-
sphere5(20,-86,-2) 
0.038357 0.00041882 0.014314 2.1104 3.8665 2.653 
0.038529 
sphere5(37,-81,1)-
sphere5(38,-17,45) 
0.038529 0.02727 0.038269 2.1123 2.297 2.2003 
0.038634 
sphere5(-21,-31,61)-
sphere5(-26,-90,3) 
0.012064 0.038634 0.033842 2.5863 2.1425 2.2603 
0.044406 
sphere5(-21,-31,61)-
sphere5(29,-77,25) 
0.0085123 0.027058 0.044406 2.7193 2.3019 2.1243 
0.046861 
sphere5(-21,-31,61)-
sphere5(-40,-88,-6) 
0.0077414 0.046861 0.017283 2.7342 2.0557 2.55 
 
 
Table 7. Significance of min(max(p)) values for all 13 parcellations (no global signal 
regression). 
Parcellation min(max(p+)) min(max(p)) p(min(max(p+))) p(min(max(p))) 
AAL 0.0607935 0.112189  0.208 0.426 
Craddock130 0.0503968 0.242712 0.152 0.831 
Craddock260 0.0294203 0.148728 0.170 0.843 
Craddock500 0.0202304 0.0909226 0.206 0.859 
Craddock950 0.0172931 0.0542509 0.316 0.815 
Shen100 0.0371887 0.376232 0.055* 0.905 
Shen200 0.0425589 0.151199 0.195 0.747 
Shen300 0.0324906 0.115015 0.199 0.804 
OASIS 0.0697703 0.3402 0.208 0.938 
Power264 0.012526 0.118716 0.033* 0.846 
Gordon_surface 0.0275321 0.11095 0.185 0.846 
Talairach 0.00701726 0.0339528 0.032* 0.522 
Stanford 0.0599084 0.281706 0.145 0.820 
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Table 8. Marginally significant FC changes w.r.t. all 3 datasets (decreased in PD). 
Parcellation p(min(max(p+))) min(max(p+)) ROI1 ROI2 
Talairach 0.032 0.00701726 
(-24,-58,4)  
left visual association 
area, lingual gyrus, 
BA18 
(–38, –32,16)  
left superior temporal gyrus, 
BA41, planum temporale / 
parietal operculum 
Power264 0.033 0.012526 
sphere5(-21,-31,61)  
left postcentral / 
precentral gyrus 
sphere5(15, –77,31)  
right cuneus 
Shen100 0.055 0.0371887 
L.BA19.3  
left cuneus, precuneus 
R.BA6.1 
right SMA, middle cingulate 
 
 
Fig 5. Marginally significant FC changes w.r.t. all 3 datasets. The ROIs were mapped onto the 
brain surface using BrainNet Viewer [Xia et al., 2013] (http://www.nitrc.org/projects/bnv/). 
 
Testing classifiers for discriminating PD-related FC changes 
Training classifiers on functional connectivity data for each one of the 3 datasets (NEUROCON, 
Tao Wu, PPMI) and testing them on the other two datasets produced average accuracies on test 
data in the range 0.225 - 0.7 (mean 0.497, standard deviation 0.073), while a random classifier is 
expected to have an average accuracy of 0.5. Fig 6 shows the corresponding average accuracies 
Aacc = (acc(NC)+acc(PD))/2 for standard preprocessing (with the default FSL highpass filter at 
0.01Hz), global signal regression and respectively bandpass filtering (0.01-0.1Hz) for both linear 
SVM and Gaussian Naïve Bayes (GNB) classifiers with N=5000 features (out of the total of 6670 
ROI pairs of the AAL parcellation). See Supplementary Fig 2 and Supplementary Table 5 for the 
accuracies of classifiers with N=10,50,100,500,5000 features. 
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Since for each training dataset (for example NEUROCON), we have two different test datasets 
(PPMI and TaoWu in our example), we also computed an aggregated average accuracy for each 
dataset by taking the mean of the two average accuracies corresponding to the two remaining test 
datasets (Aacc(dataset-dataset1)+Aacc(dataset-dataset2))/2. The resulting aggregated average 
accuracies were low, in the range 0.336 - 0.591 (mean 0.497, standard deviation 0.0522, compared 
to 0.5 for a random classifier; see also Fig 7). 
Since the three datasets are not technically homogeneous, we also trained and tested classifiers on 
random splits of the same dataset, to check to what extent the low accuracies are due to technical 
differences, or to disease heterogeneity. Fig 8 shows the average accuracies for 10,000 random 
splits in half of each dataset and various preprocessing options. Again, the means of the average 
accuracies over the 10,000 tests were low, in the range 0.51 – 0.66, reinforcing the evidence for 
disease heterogeneity. 
 
 
Fig 6. Average accuracies for classifiers trained on dataset 1 and tested on dataset 2 for all 
dataset pairs using standard preprocessing (‘standard’), global signal regression (GS) and 
respectively bandpass filtering (0.01-0.1Hz). Here, SVM (linear Support Vector Machine) and 
GNB (Gaussian Naïve Bayes) classifiers used N=5000 features – see Supplementary Fig 2 for 
classifier accuracies for varying N. As an example, NEUROCON-PPMI denotes classifiers trained 
on NEUROCON and tested on PPMI data. 
 23 
 
Fig 7. Aggregated average accuracies for classifiers trained on each of the 3 datasets using 
standard preprocessing (‘standard’), global signal regression (GS) and respectively bandpass 
filtering (0.01-0.1Hz). Classifiers were trained with N=10,50,100,500,5000 features. As an example, 
NEUROCON(10) refers to the aggregated accuracy (Aacc(NEUROCON-PPMI) + 
Aacc(NEUROCON-TaoWu))/2 for classifiers trained on NEUROCON and tested on PPMI and 
respectively TaoWu data using N=10 features. SVM – linear SVM classifier, GNB – Gaussian 
Naïve Bayes classifier. 
 
Fig 8. Average accuracies for classifiers trained and tested on split data from the same dataset 
using standard preprocessing (‘standard’), global signal regression (GS) and respectively bandpass 
filtering (0.01-0.1Hz). An SVM classifier with N=5000 features was used. 
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Discussion 
The accelerated increase in the number of functional connectivity studies of Parkinson’s Disease 
requires a consolidation of the knowledge in this field for enabling the development of clinically 
relevant rs-fMRI markers for this disease. Unfortunately however, there are many inconsistencies 
between published works and virtually no high confidence reproducibility studies.  
This is the first study investigating the reproducibility of functional connectivity changes in 
Parkinson’s disease on more than two datasets. The fact that we use a uniform data processing 
workflow for all datasets excludes a large number of technical factors as potential culprits for the 
observed differences between datasets. Also, the fact that our comparison involves three datasets is 
essential, as it lowers the probability that the observed lack of reproducibility is due to a 
problematic dataset – in such a case, with 3 datasets we might still observe reproducibility with 
respect to the remaining dataset pair, something which we do not see in reality. 
To better clarify the issue, we devised a method to directly check for disease heterogeneity using 
random splits of a single dataset with replicate scans. Technical differences can then be excluded 
since all the scans have been acquired under identical technical conditions. The fact that we still 
observe non-reproducibility in a significant fraction of random subsamples of each individual 
dataset (these subsamples being technically homogeneous as they come from the same dataset), 
suggests that functional heterogeneity may be a dominating factor behind the lack of 
reproducibility of functional connectivity alterations in different resting state fMRI studies of 
Parkinson’s disease.  
This could be due to the heterogeneous multi-lesional topography and progression of the 
neurodegenerative process, possibly accompanied by variable compensatory functional circuit 
changes, as well as by changes due to dopaminergic medication [Tahmasian et al., 2015]. 
For a a more direct graphical depiction of the heterogeneity of the functional connectomes of the 
PD patients, we have applied consensus NMF clustering [Brunet et al., 2004] for a progressively 
increasing number of clusters (k=2,…,18, Supplementary Fig 3). Note that besides the consistent 
grouping of the replicate scan pairs for each patient, it is difficult to single out an optimal number 
of clusters k. 
While global PD-related functional connectivity differences were non-reproducible across datasets, 
we identified a few individual ROI pairs with marginally consistent FC differences across all three 
datasets. However, finding out whether these differences are more widely reproducible or not will 
have to await the release of more public PD datasets. 
Additionally, we applied more sophisticated multivariate machine learning techniques to learn 
classifiers that discriminate PD from controls using functional connectivities between ROI pairs as 
features. However, training classifiers on each one of the three datasets (NEUROCON, Tao Wu, 
PPMI) produced only low accuracies on the remaining two (test) datasets, in line with the 
preceding results. Furthermore, since the three datasets are not technically homogeneous, we also 
trained and tested classifiers on random splits of the same dataset, to more directly check to what 
extent the low accuracies are due to technical differences, or to disease heterogeneity. Again, we 
obtained low average accuracies (with means in the range 0.51 – 0.66), reinforcing the evidence for 
disease heterogeneity. Interestingly, these results are consistent with a recent study [Orban et al., 
2017] on multisite generalizability of schizophrenia diagnosis based on functional brain 
connectivity, which reported multisite classification accuracies below 70%, in contrast to over 30 
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previously published, largely single-site schizophrenia studies, whose average reported 
classification accuracy exceeds 80%. 
Therefore, given the paucity of publicly available rs-fMRI PD datasets, we advocate the critical 
importance of data sharing for enabling the discovery of reproducible and clinically useful 
functional imaging biomarkers of PD. In this regard, we view our study as an important first step 
towards more refined reproducibility studies that would be possible only with more publicly 
available datasets. In view of the many inconsistencies found in the published literature on PD-
related functional connectivity changes, we strongly argue for a direct computational comparison of 
PD rs-fMRI datasets using a uniform data processing workflow, to avoid publication bias as well as 
processing workflow differences in the separate studies. 
Limitations. The present study has concentrated on PD-related changes in functional connectivity 
(loosely viewed as correlations between different regions of interest), rather than changes in 
fluctuations of the amplitude of the rs-fMRI signal. In a complementary study, [Wu et al., 2015] 
observed PD-related changes in ALFF, but with rather limited reproducibility. An in-depth analysis 
of the reproducibility of PD-related differences in the amplitude of fluctuations is out of the scope 
of the present paper. 
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Resting-state fMRI studies of Parkinson’s disease 
 
Supplementary Table 1. Resting-state fMRI studies of Parkinson’s disease 
Study Main study characteristics 
eyes open / 
closed 
NC PD Patient characteristics 
Gottlich 2013 
graphs, AAL, AAL subdivision in 
343 cortical & subcortical ROIs 
eyes closed 20 37 
advanced disease, on medication 
(L-dopa, agonists) 
Long 2012 
classifier: SVM (ALFF, ReHo, 
RFCS, GM, WM, CSF) accuracy 
86.96%, sensitivity 78.95%, 
specificity 92.59%, precision 88% 
eyes closed 27 19 
early stage (H&Y 1-2), OFF (12 
h) 
Skidmore 
2013 
classifier (ALFF): accuracy 88%, 
sensitivity 92%, specificity 87%, 
precision 87% 
eyes closed 15 14 OFF(12-18 h) 
Baudrexel 
2011  
FC STN, M1 hand area eyes closed 44 31 
early stage PD patients (n=31) 
during the medication-off state 
with healthy controls (n=44); 16 
tremor, 15 non-tremor 
Wu 2011 
FC pre-SMA - M1 
seeds: pre-SMA, M1, PCC 
eyes closed 18 18 
akinesia right (at most mild 
tremor), OFF (12h) H&Y 1.78+-
0.5 
Kwak 2010 
6 striatal seeds: 3 caudate (inferior 
ventral striatum, superior ventral 
striatum, dorsal caudate), 3 
putamen (dorsal caudal putamen, 
dorsal rostral putamen, ventral 
rostral putamen)  
eyes fixed 
on cross 
24 25 
mild to moderate stage (H&Y 1-
2.5), ON and OFF(12–18 h) 
Kwak 2012 ALFF (fALLF)   24 24 
mild to moderate stage (H&Y 1-
2.5) ON and OFF (12-18h) 
Helmich 2010  
FC anterior, posterior putamen, 
caudate 
posterior cingulate (control) 
eyes closed 36 41 
13 PD without any tremor, 18 
moderate to severe. 
10 - never anti-PD medication 
(median H&Y 2.1, max 5) 
perfectly age-matched (57 years) 
Helmich 2011 tremor eyes closed 36 41 
19 tremor, 23 nontremor, right-
handed, 12 no medication, OFF 
(12 h) 
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Luo 2014 
FC anterior, posterior putamen, 
anterior caudate, amygdala 
eyes closed 52 52 
52 PD right handed, early stage 
drug-naïve, H&Y 1.85 (max 3), 
31 right onset, 21 left onset 
Yu 2013 FC putamen, caudate, and SMA   20 19 
OFF 
obvious at least a mild tremor 
Hacker 2012 
FC striatum 
6 ROIs: (i) caudate nucleus; (ii) 
anterior putamen; and (iii) posterior 
putamen 
eyes open 
(fixate 
cross) 
19 13 advanced PD ON 
Kurani 2015 
FC (restricted to motor areas) 
seeds: STN (most affected part), 
posterior cingulate (control seed) 
eyes open 
(focused 
on the 
word 
“RELAX”) 
19 39 
20 de novo 
19 moderate OFF 
Baggio 2015 
cognitive impairement 
ICA+dual regression (25 networks), 
group comparison of: DMN, dorsal 
attention network (DAN), bilateral 
frontoparietal networks (FPN), 
43 seeds (10 DAN, 18 DMN, 15 
FPN) 
  36 65 
ON state 
65 nondemented: 34% mild 
cognitive impairement (MCI) 
Esposito 2013 
ICA (fastICA BrainVoyager 40 
components, restriction to 
sensorimotor network-best fit with 
previous template) 
eyes closed 18 20 
20 drug naïve PD, 10 before & 
after  (1H) levodopa, 10 before & 
after placebo  
Szewczyk-
Krolikowski 
2014 
ICA+dual regression – basal 
ganglia (BG) network from 80 
separate controls 
- classifier based on average BG 
component values in voxels 
discriminating PD(OFF)-controls 
eyes open 19 19 
discovery cohort: 19 PD 
ON/OFF, 19 controls 
validation cohort: 13 PD (5 drug-
naïve), no controls (this 
disallows evaluation of 
specificity!) 
80 elderly controls for BG 
template (MELODIC groupICA 
50 components) 
all subjects right-handed 
Tessitore 
2012 
fastICA, sogICA  
40 components 
select DMN, the frontoparietal 
(right and left FPN), sensorimotor 
network (SMN), visual, auditory  
eyes closed 15 29 
PD ON 
16 FOG+ 
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Sharman 2013 
ROIs: caudate, putamen, globus 
pallidus, thalamus 
sensorimotor (M1, postcentral 
gyrus) 
associative (ventrolateral, 
dorsolateral prefrontal) 
limbic (orbitofrontal, rectus gyrus, 
cingulate, insula, medial temporal 
ctx, perirhinal & entorhinal cortex, 
hippocampus, amygdala) 
eyes closed 45 36   
Wu 2012 
ROIs: SNc bilaterally  
effective connectivity Granger 
causality analysis (GCA) 
with long TR=2000 & short 
TR=400 
eyes closed 16 16 
16 de novo 
OFF/ON 
Liu 2013 
FC dentate nucleus (cerebellum) -> 
cerebellar output 
eyes closed 18 18 
mild to moderate (1.34 H&Y 
average) 
in OFF state 
8 rigidity & bradykinesia-
dominant (PD_AR)  
10 tremor-dominant (PD_T) 
Chen 2015 
SVM classifier LOOCV based on 
FC between 116 ROIs of AAL 
parcellation (150 features selected 
by Kendall tau correlation) - 
93.62% accuracy, 90.47% 
sensitivity, 96.15 specificity 
eyes closed 26 21 
21 PD (10 males, 11 females, 
58.3 years), 26 HC (10 males, 16 
females, 61.3 years) OFF state 
(12 hours) UPDRS 29.8 (sd 9.1), 
disease duration 3.2 years (sd 
3.2) 
Wen 2013 
depression 
ALFF 
eyes closed 21 33 
OFF 
17 depression 
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Subject motion in scanner 
 
Since subject motion in the scanner has been observed to have significant influence on the 
functional connectivities computed from rs-fMRI data, despite motion correction (e.g. [Power et al., 
2015]), we also considered subsets of scans with low in-scanner motion (marked by the suffix ‘0’, 
e.g. ‘NC0’ and ‘PD0’ – see also Supplementary Table 2). The 3 datasets have different in-scanner 
motion characteristics. 
Supplementary Table 2. The subsets of scans with low in-scanner motion 
Dataset Low motion condition NC scans PD scans NC0 scans PD0 scans 
NEUROCON max abs motion  1/4 voxel = 0.958mm 
max rel motion  1/6 voxel = 0.638mm 
31 54 27 39 
Tao Wu max abs motion  1/4 voxel = 1mm 
max rel motion  1/6 voxel = 0.67mm 
20 20 13 14 
PPMI max abs motion  1/3 voxel = 1.098mm 
max rel motion  1/3 voxel = 1.098mm 
mean abs motion  1/6 voxel = 0.549mm 
max rel motion  1/6 voxel = 0.549mm 
19 134 13 89 
 
The following Tables show the p-values corresponding to potential group differences in motion in 
the 3 datasets analyzed: 
 
NEUROCON 
NC-PD (31-54)    p-value (t-value) 
p(mean rel) p(mean abs) p(max rel) p(max abs) 
0.00243021 
(-3.14036) 
0.0545481 
(-1.96039) 
0.0945346 
(-1.6961) 
0.135713 
(-1.50937) 
 
NC0-PD0 (27-39) 
p(mean rel) p(mean abs) p(max rel) p(max abs) 
0.166962 
(-1.39829) 
0.043621 
(-2.06138) 
0.319776 
(-1.00337) 
0.100148 
(-1.67026) 
 
Note that in the NEUROCON cohort, patients move more than normal controls. 
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Tao Wu  
NC-PD (20-20) 
p(mean rel) p(mean abs) p(max rel) p(max abs) 
0.0270361 
(2.33514) 
0.727106 
(0.352521) 
0.0074933 
(2.96994) 
0.543508 
(0.613522) 
 
NC0-PD0 (13-14) 
p(mean rel) p(mean abs) p(max rel) p(max abs) 
0.256895 
(1.16397) 
0.497445 
(0.688602) 
0.0859714 
(1.80121) 
0.455533 
(0.758043) 
 
In the Tao Wu cohort, patients move less than normal controls. 
 
PPMI 
 
NC-PD (19-134) 
p(mean rel) p(mean abs) p(max rel) p(max abs) 
0.0619124 
(1.9849) 
0.485967 
(0.710965) 
0.107866 
(1.69169) 
0.134632 
(1.56558) 
 
NC0-PD0 (13-89) 
p(mean rel) p(mean abs) p(max rel) p(max abs) 
0.0656489 
(1.94269) 
0.314195 
(-1.03452) 
0.224242  
(1.26499) 
0.53616  
(0.63367) 
 
NC_center32-PD_center32 (9-30) 
p(mean rel) p(mean abs) p(max rel) p(max abs) 
0.242348 
(1.23728) 
0.77672 
(0.289486) 
0.344483 
(1.00257) 
0.318376 
(1.05993) 
 
NC0_center32-PD0_center32 (7-23) 
p(mean rel) p(mean abs) p(max rel) p(max abs) 
0.173686 
(1.40637) 
0.649951 
(0.46271) 
0.252684 
(1.21065) 
0.13755 
(1.64485) 
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ROI-pairs with significant group differences in the separate datasets 
 
Supplementary Table 3 below shows the numbers of significant ROI pairs for several significance 
thresholds for the unpaired t-test between patient and control functional connectivities (for the AAL 
parcellation and without correction for multiple comparisons, due to the limited sample sizes). A 
single scan for each subject was considered in this comparison. 
 
Supplementary Table 3. Number of significant ROI-pairs for the AAL parcellation 
significance 
level 
NEUROCON(16-27) TaoWu(20-20) PPMI(18-91) 
0.001 4 15 19 
0.005 23 68 81 
0.01 48 121 156 
0.05 283 489 737 
 
As expected, the power of the tests was greater for the datasets with more samples, but the effect 
sizes (t-values) were similar, as can be seen in Supplementary Table 4 below, which shows the top 
positive and respectively negative effect sizes observed. 
 
Supplementary Table 4. Top effect sizes (t-values) and the corresponding p-values for the top 
positive and respectively negative FC alterations 
 
NEUROCON(16-27) TaoWu(20-20) PPMI(18-91) 
top t+ 3.05647 4.632511 4.70764 
top p+ 0.00429499 4.23E-05 7.99E-05 
top t− -4.495779 -2.91725 -3.870344 
top p− 6.09E-05 0.0062734 0.0003765 
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Comparison of random splits of an ‘eyes open-eyes closed’ dataset 
Besides the potentially heterogeneous contrast between PD and normal controls, we also tested our 
method on a different, potentially more homogeneous contrast, namely ‘eyes open’ versus ‘eyes 
closed’ resting state in healthy volunteers. We used the Beijing eyes-open-eyes closed (EO-EC) 
dataset [Liu et al., 2013] (http://fcon_1000.projects.nitrc.org/indi/IndiPro.html), which involved 48  
college students aged 19–31 years, 24 female with no history of neurological and psychiatric 
disorders. Each participant underwent three 8 min resting state scanning sessions: an EC session 
followed by two sessions counter-balanced across subjects: one EO resting state and one EC resting 
state session.  
The functional images were obtained on a Siemens Trio 3 Tesla scanner using an echo-planar 
imaging sequence with the following parameters: 33 axial slices, thickness/gap=3.5/0.7 mm, in-
plane resolution=64×64, repetition time=2000 ms, echo time=30 ms, flip angle=90°, field of view 
(FOV)=200×200mm
2
, 240 volumes per scan. In addition, a 3D T1-weighted MPRAGE image was 
acquired with the following parameters: 128 sagittal slices, slice thickness/gap=1.33/0 mm, in-
plane resolution=256×192, TR=2530 ms, TE=3.39 ms, inversion time (TI)=1100 ms, flip angle=7°, 
FOV=256×256 mm
2
. Note that the parameters used in this study are quite similar to the ones from 
the PD datasets, including the scanning time (~8 min), with the exception of the 1.5 Tesla field 
strength used in the NEUROCON study (all the other studies used 3 Tesla machines). 
We repeated our analyses of reproducibility of group changes in functional connectivity on random 
splits of the Beijing EO-EC dataset on both “split subjects” (heterogeneous) and “split replicates” 
(homogeneous) datasets using the AAL parcellation. As in the case of PD, permutation tests were 
employed to compute p-values of the reproducibility across split datasets. Additionally, we 
repeated the analysis for the data with global signal regression. 
‘Eyes Open-Eyes Closed’ FC changes are reproducible 
The fact that the well-known clinical heterogeneity of Parkinson’s disease is also accompanied by 
heterogeneity in resting state functional connectivity may not retrospectively be a big surprise to an 
experienced neurologist, although its exact extent could not have been estimated a priori, before 
analyzing the data. 
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However, does this FC heterogeneity in PD also imply the lack of practical usefulness of rs-fMRI 
functional connectivity? Are there any other conditions that can be reliably differentiated using 
resting state functional connectivity? To answer these questions, we applied our approach to a 
different, potentially more homogeneous contrast, namely that between eyes open and eyes closed 
resting state conditions in healthy volunteers. Repeating our analysis of reproducibility of FC group 
changes on random splits of the Beijing eyes open-eyes closed dataset [Liu et al., 2013] revealed 
reproducibility (p<0.05) not just in the homogeneous dataset splits, but also in the heterogeneous 
ones (Supplementary Fig 1 – only 6% of the heterogeneous and just 0.8% of the homogeneous 
random splits were non-reproducible at the p>0.05 level). This implies that the EO-EC contrast 
produces more homogeneous and reproducible global FC changes. 
 
Supplementary Fig 1. Consistent reproducibility of ‘eyes open’-‘eyes closed’ (EO-EC) FC 
changes in random heterogeneous and homogeneous dataset splits. (A) Complementary 
cumulative distribution function (CCDF=1-CDF) of the reproducibility p-values for Ns=1056 
random heterogeneous splits and Ns=814 random homogeneous splits. (B) CCDF of the 
reproducibility measure R. (C) A scatter-plot of ROI-pair t-values for a random heterogeneous split. 
(D) A scatter-plot of ROI-pair t-values for a random homogeneous split. 
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Learning classifiers for discriminating PD-related FC changes 
  
 
 
Supplementary Fig 2. Average accuracies Aacc = (acc(NC)+acc(PD))/2 for classifiers trained 
on dataset 1 and tested on dataset 2 for all dataset pairs using standard preprocessing 
(‘standard’), global signal regression (GS) and respectively bandpass filtering (0.01-0.1Hz). 
Classifiers were trained with N=10,50,100,500,5000 features. For example, NEUROCON-
PPMI(10) shows average accuracies of classifiers trained on NEUROCON and tested on PPMI data 
using N=10 features. SVM – linear SVM classifier, GNB – Gaussian Naïve Bayes classifier.  
Supporting information 39 
Supplementary Table 5. Detailed performance metrics for the various classifiers 
TRAIN 
DATASET 
TEST 
DATASET classifier 
N 
pairs 
Pre-
processing 
TEST 
AvgaccPer
Class 
TEST 
accPerCl
ass(NC) 
TEST 
accPerCla
ss(PD) 
NEUROCON PPMI gnb_pooled 10 standard 0.526709 0.1579 0.895522 
NEUROCON PPMI svm_linear 10 standard 0.452082 0.1579 0.746269 
NEUROCON PPMI gnb_pooled 50 standard 0.447761 0 0.895522 
NEUROCON PPMI svm_linear 50 standard 0.462687 0 0.925373 
NEUROCON PPMI gnb_pooled 100 standard 0.410644 0.05263 0.768657 
NEUROCON PPMI svm_linear 100 standard 0.421642 0 0.843284 
NEUROCON PPMI gnb_pooled 500 standard 0.433032 0.05263 0.813433 
NEUROCON PPMI svm_linear 500 standard 0.49293 0.10526 0.880597 
NEUROCON PPMI gnb_pooled 5000 standard 0.466614 0.05263 0.880597 
NEUROCON PPMI svm_linear 5000 standard 0.530833 0.26316 0.798507 
NEUROCON TaoWu gnb_pooled 10 standard 0.35 0.2 0.5 
NEUROCON TaoWu svm_linear 10 standard 0.4 0.15 0.65 
NEUROCON TaoWu gnb_pooled 50 standard 0.225 0.15 0.3 
NEUROCON TaoWu svm_linear 50 standard 0.5 0.15 0.85 
NEUROCON TaoWu gnb_pooled 100 standard 0.275 0.15 0.4 
NEUROCON TaoWu svm_linear 100 standard 0.45 0.05 0.85 
NEUROCON TaoWu gnb_pooled 500 standard 0.325 0.2 0.45 
NEUROCON TaoWu svm_linear 500 standard 0.425 0.05 0.8 
NEUROCON TaoWu gnb_pooled 5000 standard 0.35 0.25 0.45 
NEUROCON TaoWu svm_linear 5000 standard 0.45 0.1 0.8 
PPMI NEUROCON gnb_pooled 10 standard 0.491637 0.6129 0.37037 
PPMI NEUROCON svm_linear 10 standard 0.471326 0.3871 0.555556 
PPMI NEUROCON gnb_pooled 50 standard 0.486858 0.67742 0.296296 
PPMI NEUROCON svm_linear 50 standard 0.501493 0.35484 0.648148 
PPMI NEUROCON gnb_pooled 100 standard 0.519116 0.74194 0.296296 
PPMI NEUROCON svm_linear 100 standard 0.490143 0.25807 0.722222 
PPMI NEUROCON gnb_pooled 500 standard 0.576762 0.83871 0.314815 
PPMI NEUROCON svm_linear 500 standard 0.471924 0.12903 0.814815 
PPMI NEUROCON gnb_pooled 5000 standard 0.542413 0.67742 0.407407 
PPMI NEUROCON svm_linear 5000 standard 0.439665 0.06452 0.814815 
PPMI TaoWu gnb_pooled 10 standard 0.45 0.85 0.05 
PPMI TaoWu svm_linear 10 standard 0.7 0.6 0.8 
PPMI TaoWu gnb_pooled 50 standard 0.475 0.8 0.15 
PPMI TaoWu svm_linear 50 standard 0.55 0.3 0.8 
PPMI TaoWu gnb_pooled 100 standard 0.5 0.85 0.15 
PPMI TaoWu svm_linear 100 standard 0.625 0.35 0.9 
PPMI TaoWu gnb_pooled 500 standard 0.55 0.9 0.2 
PPMI TaoWu svm_linear 500 standard 0.575 0.15 1 
PPMI TaoWu gnb_pooled 5000 standard 0.6 0.85 0.35 
PPMI TaoWu svm_linear 5000 standard 0.575 0.15 1 
TaoWu NEUROCON gnb_pooled 10 standard 0.397551 0.25807 0.537037 
TaoWu NEUROCON svm_linear 10 standard 0.41368 0.29032 0.537037 
TaoWu NEUROCON gnb_pooled 50 standard 0.462366 0.25807 0.666667 
TaoWu NEUROCON svm_linear 50 standard 0.397252 0.3871 0.407407 
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TaoWu NEUROCON gnb_pooled 100 standard 0.480884 0.25807 0.703704 
TaoWu NEUROCON svm_linear 100 standard 0.443548 0.3871 0.5 
TaoWu NEUROCON gnb_pooled 500 standard 0.503883 0.32258 0.685185 
TaoWu NEUROCON svm_linear 500 standard 0.41368 0.29032 0.537037 
TaoWu NEUROCON gnb_pooled 5000 standard 0.476105 0.32258 0.62963 
TaoWu NEUROCON svm_linear 5000 standard 0.448626 0.19355 0.703704 
TaoWu PPMI gnb_pooled 10 standard 0.493912 0.36842 0.619403 
TaoWu PPMI svm_linear 10 standard 0.539081 0.47368 0.604478 
TaoWu PPMI gnb_pooled 50 standard 0.629419 0.68421 0.574627 
TaoWu PPMI svm_linear 50 standard 0.499018 0.73684 0.261194 
TaoWu PPMI gnb_pooled 100 standard 0.614493 0.68421 0.544776 
TaoWu PPMI svm_linear 100 standard 0.518068 0.84211 0.19403 
TaoWu PPMI gnb_pooled 500 standard 0.599568 0.68421 0.514925 
TaoWu PPMI svm_linear 500 standard 0.483896 0.68421 0.283582 
TaoWu PPMI gnb_pooled 5000 standard 0.625687 0.68421 0.567164 
TaoWu PPMI svm_linear 5000 standard 0.547722 0.78947 0.30597 
NEUROCON PPMI gnb_pooled 10 GS 0.515318 0.10526 0.925373 
NEUROCON PPMI svm_linear 10 GS 0.458955 0 0.91791 
NEUROCON PPMI gnb_pooled 50 GS 0.575805 0.31579 0.835821 
NEUROCON PPMI svm_linear 50 GS 0.571485 0.1579 0.985075 
NEUROCON PPMI gnb_pooled 100 GS 0.526905 0.21053 0.843284 
NEUROCON PPMI svm_linear 100 GS 0.522584 0.05263 0.992537 
NEUROCON PPMI gnb_pooled 500 GS 0.49293 0.10526 0.880597 
NEUROCON PPMI svm_linear 500 GS 0.500393 0.10526 0.895522 
NEUROCON PPMI gnb_pooled 5000 GS 0.522977 0.1579 0.88806 
NEUROCON PPMI svm_linear 5000 GS 0.538885 0.42105 0.656716 
NEUROCON TaoWu gnb_pooled 10 GS 0.5 0.2 0.8 
NEUROCON TaoWu svm_linear 10 GS 0.425 0.15 0.7 
NEUROCON TaoWu gnb_pooled 50 GS 0.5 0.4 0.6 
NEUROCON TaoWu svm_linear 50 GS 0.4 0.05 0.75 
NEUROCON TaoWu gnb_pooled 100 GS 0.475 0.45 0.5 
NEUROCON TaoWu svm_linear 100 GS 0.425 0 0.85 
NEUROCON TaoWu gnb_pooled 500 GS 0.45 0.6 0.3 
NEUROCON TaoWu svm_linear 500 GS 0.6 0.25 0.95 
NEUROCON TaoWu gnb_pooled 5000 GS 0.375 0.55 0.2 
NEUROCON TaoWu svm_linear 5000 GS 0.575 0.15 1 
PPMI NEUROCON gnb_pooled 10 GS 0.623656 0.58065 0.666667 
PPMI NEUROCON svm_linear 10 GS 0.499403 0.25807 0.740741 
PPMI NEUROCON gnb_pooled 50 GS 0.549881 0.45161 0.648148 
PPMI NEUROCON svm_linear 50 GS 0.488053 0.16129 0.814815 
PPMI NEUROCON gnb_pooled 100 GS 0.462366 0.25807 0.666667 
PPMI NEUROCON svm_linear 100 GS 0.51135 0.09677 0.925926 
PPMI NEUROCON gnb_pooled 500 GS 0.595878 0.58065 0.611111 
PPMI NEUROCON svm_linear 500 GS 0.502091 0.09677 0.907407 
PPMI NEUROCON gnb_pooled 5000 GS 0.616487 0.67742 0.555556 
PPMI NEUROCON svm_linear 5000 GS 0.423536 0.03226 0.814815 
PPMI TaoWu gnb_pooled 10 GS 0.525 0.45 0.6 
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PPMI TaoWu svm_linear 10 GS 0.575 0.4 0.75 
PPMI TaoWu gnb_pooled 50 GS 0.45 0.45 0.45 
PPMI TaoWu svm_linear 50 GS 0.575 0.3 0.85 
PPMI TaoWu gnb_pooled 100 GS 0.575 0.45 0.7 
PPMI TaoWu svm_linear 100 GS 0.65 0.35 0.95 
PPMI TaoWu gnb_pooled 500 GS 0.475 0.35 0.6 
PPMI TaoWu svm_linear 500 GS 0.6 0.2 1 
PPMI TaoWu gnb_pooled 5000 GS 0.55 0.55 0.55 
PPMI TaoWu svm_linear 5000 GS 0.575 0.2 0.95 
TaoWu NEUROCON gnb_pooled 10 GS 0.459976 0.29032 0.62963 
TaoWu NEUROCON svm_linear 10 GS 0.434588 0.25807 0.611111 
TaoWu NEUROCON gnb_pooled 50 GS 0.413978 0.16129 0.666667 
TaoWu NEUROCON svm_linear 50 GS 0.446237 0.22581 0.666667 
TaoWu NEUROCON gnb_pooled 100 GS 0.434588 0.25807 0.611111 
TaoWu NEUROCON svm_linear 100 GS 0.441458 0.29032 0.592593 
TaoWu NEUROCON gnb_pooled 500 GS 0.436679 0.35484 0.518519 
TaoWu NEUROCON svm_linear 500 GS 0.443548 0.3871 0.5 
TaoWu NEUROCON gnb_pooled 5000 GS 0.408901 0.35484 0.462963 
TaoWu NEUROCON svm_linear 5000 GS 0.452808 0.3871 0.518519 
TaoWu PPMI gnb_pooled 10 GS 0.536332 0.73684 0.335821 
TaoWu PPMI svm_linear 10 GS 0.513354 0.57895 0.447761 
TaoWu PPMI gnb_pooled 50 GS 0.520228 0.42105 0.619403 
TaoWu PPMI svm_linear 50 GS 0.388845 0.21053 0.567164 
TaoWu PPMI gnb_pooled 100 GS 0.512962 0.47368 0.552239 
TaoWu PPMI svm_linear 100 GS 0.535546 0.52632 0.544776 
TaoWu PPMI gnb_pooled 500 GS 0.630204 0.89474 0.365672 
TaoWu PPMI svm_linear 500 GS 0.532011 0.57895 0.485075 
TaoWu PPMI gnb_pooled 5000 GS 0.577965 0.89474 0.261194 
TaoWu PPMI svm_linear 5000 GS 0.562451 0.73684 0.38806 
NEUROCON PPMI gnb_pooled 10 bandpass 0.519049 0.10526 0.932836 
NEUROCON PPMI svm_linear 10 bandpass 0.437156 0.1579 0.716418 
NEUROCON PPMI gnb_pooled 50 bandpass 0.459348 0.10526 0.813433 
NEUROCON PPMI svm_linear 50 bandpass 0.462883 0.05263 0.873134 
NEUROCON PPMI gnb_pooled 100 bandpass 0.467203 0.21053 0.723881 
NEUROCON PPMI svm_linear 100 bandpass 0.440888 0.1579 0.723881 
NEUROCON PPMI gnb_pooled 500 bandpass 0.425766 0.10526 0.746269 
NEUROCON PPMI svm_linear 500 bandpass 0.481932 0.1579 0.80597 
NEUROCON PPMI gnb_pooled 5000 bandpass 0.414375 0.05263 0.776119 
NEUROCON PPMI svm_linear 5000 bandpass 0.497054 0.21053 0.783582 
NEUROCON TaoWu gnb_pooled 10 bandpass 0.475 0.15 0.8 
NEUROCON TaoWu svm_linear 10 bandpass 0.525 0.35 0.7 
NEUROCON TaoWu gnb_pooled 50 bandpass 0.475 0.35 0.6 
NEUROCON TaoWu svm_linear 50 bandpass 0.5 0.25 0.75 
NEUROCON TaoWu gnb_pooled 100 bandpass 0.525 0.45 0.6 
NEUROCON TaoWu svm_linear 100 bandpass 0.575 0.35 0.8 
NEUROCON TaoWu gnb_pooled 500 bandpass 0.475 0.35 0.6 
NEUROCON TaoWu svm_linear 500 bandpass 0.7 0.4 1 
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NEUROCON TaoWu gnb_pooled 5000 bandpass 0.5 0.5 0.5 
NEUROCON TaoWu svm_linear 5000 bandpass 0.65 0.35 0.95 
PPMI NEUROCON gnb_pooled 10 bandpass 0.448626 0.19355 0.703704 
PPMI NEUROCON svm_linear 10 bandpass 0.464456 0.35484 0.574074 
PPMI NEUROCON gnb_pooled 50 bandpass 0.469235 0.29032 0.648148 
PPMI NEUROCON svm_linear 50 bandpass 0.432796 0.03226 0.833333 
PPMI NEUROCON gnb_pooled 100 bandpass 0.459976 0.29032 0.62963 
PPMI NEUROCON svm_linear 100 bandpass 0.483572 0.09677 0.87037 
PPMI NEUROCON gnb_pooled 500 bandpass 0.485364 0.32258 0.648148 
PPMI NEUROCON svm_linear 500 bandpass 0.488351 0.03226 0.944444 
PPMI NEUROCON gnb_pooled 5000 bandpass 0.476105 0.32258 0.62963 
PPMI NEUROCON svm_linear 5000 bandpass 0.481481 0 0.962963 
PPMI TaoWu gnb_pooled 10 bandpass 0.475 0.2 0.75 
PPMI TaoWu svm_linear 10 bandpass 0.55 0.5 0.6 
PPMI TaoWu gnb_pooled 50 bandpass 0.5 0.4 0.6 
PPMI TaoWu svm_linear 50 bandpass 0.475 0.15 0.8 
PPMI TaoWu gnb_pooled 100 bandpass 0.475 0.45 0.5 
PPMI TaoWu svm_linear 100 bandpass 0.45 0.2 0.7 
PPMI TaoWu gnb_pooled 500 bandpass 0.475 0.4 0.55 
PPMI TaoWu svm_linear 500 bandpass 0.525 0.1 0.95 
PPMI TaoWu gnb_pooled 5000 bandpass 0.45 0.45 0.45 
PPMI TaoWu svm_linear 5000 bandpass 0.55 0.1 1 
TaoWu NEUROCON gnb_pooled 10 bandpass 0.543309 0.29032 0.796296 
TaoWu NEUROCON svm_linear 10 bandpass 0.515532 0.29032 0.740741 
TaoWu NEUROCON gnb_pooled 50 bandpass 0.515532 0.29032 0.740741 
TaoWu NEUROCON svm_linear 50 bandpass 0.364994 0.32258 0.407407 
TaoWu NEUROCON gnb_pooled 100 bandpass 0.499403 0.25807 0.740741 
TaoWu NEUROCON svm_linear 100 bandpass 0.41129 0.32258 0.5 
TaoWu NEUROCON gnb_pooled 500 bandpass 0.506272 0.29032 0.722222 
TaoWu NEUROCON svm_linear 500 bandpass 0.506272 0.29032 0.722222 
TaoWu NEUROCON gnb_pooled 5000 bandpass 0.503883 0.32258 0.685185 
TaoWu NEUROCON svm_linear 5000 bandpass 0.490143 0.25807 0.722222 
TaoWu PPMI gnb_pooled 10 bandpass 0.568932 0.47368 0.664179 
TaoWu PPMI svm_linear 10 bandpass 0.531422 0.42105 0.641791 
TaoWu PPMI gnb_pooled 50 bandpass 0.607031 0.68421 0.529851 
TaoWu PPMI svm_linear 50 bandpass 0.480754 0.84211 0.119403 
TaoWu PPMI gnb_pooled 100 bandpass 0.621956 0.68421 0.559701 
TaoWu PPMI svm_linear 100 bandpass 0.454635 0.84211 0.067164 
TaoWu PPMI gnb_pooled 500 bandpass 0.652003 0.73684 0.567164 
TaoWu PPMI svm_linear 500 bandpass 0.473095 0.78947 0.156716 
TaoWu PPMI gnb_pooled 5000 bandpass 0.633346 0.73684 0.529851 
TaoWu PPMI svm_linear 5000 bandpass 0.547722 0.78947 0.30597 
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Consensus NMF clustering 
 
For a more direct graphical depiction of the heterogeneity of the functional connectomes of the PD 
patient scans, we have applied consensus NMF clustering [Brunet et al., 2004] for a progressively 
increasing number of clusters k=2,…,18 (Supplementary Fig 3). The Figure depicts the symmetric 
consensus co-clustering matrices for the PD scans from the NEUROCON dataset. Note that besides 
the consistent grouping of the replicate scan pairs for each patient, it is difficult to single out an 
optimal number of clusters k. 
 
 
Supplementary Fig 3. Consensus NMF clustering of functional connectomes of PD patient 
scans from the NEUROCON dataset. 
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